Cargando…

1550. Pediatric Febrile Neutropenia: Does Depth and Duration of Neutropenia at Presentation Predict Outcomes?

BACKGROUND: The 2010 Infectious Diseases Society of America (IDSA) guidelines define febrile neutropenia (FN) patients as high risk if they have profound neutropenia [ANC (absolute neutrophil count) ≤100 cells/μL] anticipated to last >7 days. Formal studies to clearly evaluate the significance of...

Descripción completa

Detalles Bibliográficos
Autores principales: Alali, Muayad, Pisano, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254864/
http://dx.doi.org/10.1093/ofid/ofy210.1378
_version_ 1783373824243269632
author Alali, Muayad
Pisano, Jennifer
author_facet Alali, Muayad
Pisano, Jennifer
author_sort Alali, Muayad
collection PubMed
description BACKGROUND: The 2010 Infectious Diseases Society of America (IDSA) guidelines define febrile neutropenia (FN) patients as high risk if they have profound neutropenia [ANC (absolute neutrophil count) ≤100 cells/μL] anticipated to last >7 days. Formal studies to clearly evaluate the significance of the depth of neutropenia are lacking. METHODS: A retrospective cohort study of all pediatric oncology patients presenting with FN between July 2009–December 2016 was performed to evaluate if the depth and duration of neutropenia prior to presentation was correlated with blood stream infection (BSI), invasive fungal disease (IFD), pediatric intensive care unit (PICU) admission or length of stay (LOS). Patients were categorized into three groups based on ANC at time of presentation: <100, 100–500, and >500 cells/mL with decreasing ANC over the subsequent 48 hours. Durations of neutropenia prior to presentation were also assessed. RESULTS: A total of 585 FN episodes (FNEs) were identified in 265 patients presenting with 411(70%) ANC <100, 119(20%) ANC 100–500 and 55 (10%) ANC >500 with subsequent decline over 48 hours. Underlying diagnoses included ALL (32%), AML (29%), lymphoma (16%), neuroblastoma (16%) and other solid tumors (9%). In group ANC >500; 70% (39/55) of received chemotherapy within 2 weeks of presentation and 35% were s/p SCT. Rates of IFD and BSI were higher in the group with ANC > 500 with decline in 48 hours compared with ANC < 100 (OR = 5.9, P = 0.03) and ANC 100–500 (OR = 5.6, P = 0.034). Patients with ANC>500 cells/mL were significantly more likely to be admitted to the PICU (OR = 5.00, P = 0.017) and had an increased LOS (hazard ratio = 0.55, P = 0.002) when compared with the other two groups. No difference in PICU admission or mortality was found when patients presenting with fevers and ANC < 100 were compared with ANC 100–500. Neutropenia ≥7 days prior to FN was an independent risk factor for BSI (OR = 2.8, P = 0.001). CONCLUSION: Pediatric patients presenting with febrile neutropenia and initial ANC >500 cells/mL with decine over 48 hours had a higher incidence of BSI, IFD, PICU admissions Clinicians should not be reassured when patients present with fever and initial ANC >500 cells/mL after undergoing recent chemotherapy if continued decline is expected. More work needs to be done to evaluate for risk factors at the time of presentation with FN to guide clinical care. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6254864
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62548642018-11-28 1550. Pediatric Febrile Neutropenia: Does Depth and Duration of Neutropenia at Presentation Predict Outcomes? Alali, Muayad Pisano, Jennifer Open Forum Infect Dis Abstracts BACKGROUND: The 2010 Infectious Diseases Society of America (IDSA) guidelines define febrile neutropenia (FN) patients as high risk if they have profound neutropenia [ANC (absolute neutrophil count) ≤100 cells/μL] anticipated to last >7 days. Formal studies to clearly evaluate the significance of the depth of neutropenia are lacking. METHODS: A retrospective cohort study of all pediatric oncology patients presenting with FN between July 2009–December 2016 was performed to evaluate if the depth and duration of neutropenia prior to presentation was correlated with blood stream infection (BSI), invasive fungal disease (IFD), pediatric intensive care unit (PICU) admission or length of stay (LOS). Patients were categorized into three groups based on ANC at time of presentation: <100, 100–500, and >500 cells/mL with decreasing ANC over the subsequent 48 hours. Durations of neutropenia prior to presentation were also assessed. RESULTS: A total of 585 FN episodes (FNEs) were identified in 265 patients presenting with 411(70%) ANC <100, 119(20%) ANC 100–500 and 55 (10%) ANC >500 with subsequent decline over 48 hours. Underlying diagnoses included ALL (32%), AML (29%), lymphoma (16%), neuroblastoma (16%) and other solid tumors (9%). In group ANC >500; 70% (39/55) of received chemotherapy within 2 weeks of presentation and 35% were s/p SCT. Rates of IFD and BSI were higher in the group with ANC > 500 with decline in 48 hours compared with ANC < 100 (OR = 5.9, P = 0.03) and ANC 100–500 (OR = 5.6, P = 0.034). Patients with ANC>500 cells/mL were significantly more likely to be admitted to the PICU (OR = 5.00, P = 0.017) and had an increased LOS (hazard ratio = 0.55, P = 0.002) when compared with the other two groups. No difference in PICU admission or mortality was found when patients presenting with fevers and ANC < 100 were compared with ANC 100–500. Neutropenia ≥7 days prior to FN was an independent risk factor for BSI (OR = 2.8, P = 0.001). CONCLUSION: Pediatric patients presenting with febrile neutropenia and initial ANC >500 cells/mL with decine over 48 hours had a higher incidence of BSI, IFD, PICU admissions Clinicians should not be reassured when patients present with fever and initial ANC >500 cells/mL after undergoing recent chemotherapy if continued decline is expected. More work needs to be done to evaluate for risk factors at the time of presentation with FN to guide clinical care. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6254864/ http://dx.doi.org/10.1093/ofid/ofy210.1378 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Alali, Muayad
Pisano, Jennifer
1550. Pediatric Febrile Neutropenia: Does Depth and Duration of Neutropenia at Presentation Predict Outcomes?
title 1550. Pediatric Febrile Neutropenia: Does Depth and Duration of Neutropenia at Presentation Predict Outcomes?
title_full 1550. Pediatric Febrile Neutropenia: Does Depth and Duration of Neutropenia at Presentation Predict Outcomes?
title_fullStr 1550. Pediatric Febrile Neutropenia: Does Depth and Duration of Neutropenia at Presentation Predict Outcomes?
title_full_unstemmed 1550. Pediatric Febrile Neutropenia: Does Depth and Duration of Neutropenia at Presentation Predict Outcomes?
title_short 1550. Pediatric Febrile Neutropenia: Does Depth and Duration of Neutropenia at Presentation Predict Outcomes?
title_sort 1550. pediatric febrile neutropenia: does depth and duration of neutropenia at presentation predict outcomes?
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254864/
http://dx.doi.org/10.1093/ofid/ofy210.1378
work_keys_str_mv AT alalimuayad 1550pediatricfebrileneutropeniadoesdepthanddurationofneutropeniaatpresentationpredictoutcomes
AT pisanojennifer 1550pediatricfebrileneutropeniadoesdepthanddurationofneutropeniaatpresentationpredictoutcomes